stoxline Quote Chart Rank Option Currency Glossary
  
SCYNEXIS, Inc. (SCYX)
2.35  0.14 (6.33%)    05-30 16:00
Open: 2.16
High: 2.45
Volume: 154,289
  
Pre. Close: 2.21
Low: 2.16
Market Cap: 89(M)
Technical analysis
2024-05-30 4:44:20 PM
Short term     
Mid term     
Targets 6-month :  3.58 1-year :  4.18
Resists First :  3.06 Second :  3.58
Pivot price 2.3
Supports First :  2.05 Second :  1.41
MAs MA(5) :  2.3 MA(20) :  2.17
MA(100) :  1.79 MA(250) :  2.18
MACD MACD :  0.1 Signal :  0.2
%K %D K(14,3) :  40.5 D(3) :  42.3
RSI RSI(14): 58
52-week High :  3.86 Low :  1.35
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ SCYX ] has closed below upper band by 45.9%. Bollinger Bands are 106.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 18 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.45 - 2.46 2.46 - 2.47
Low: 2.13 - 2.15 2.15 - 2.16
Close: 2.33 - 2.35 2.35 - 2.37
Company Description

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Headline News

Mon, 27 May 2024
SCYNEXIS, Inc. (NASDAQ:SCYX) Stock Holdings Increased by D.A. Davidson & CO. - Defense World

Sat, 25 May 2024
Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Lifestyle UK

Mon, 13 May 2024
Brokers Offer Predictions for SCYNEXIS, Inc.'s FY2026 Earnings (NASDAQ:SCYX) - Defense World

Mon, 13 May 2024
FY2026 EPS Estimates for SCYNEXIS, Inc. (NASDAQ:SCYX) Boosted by Brookline Capital Management - MarketBeat

Sun, 12 May 2024
SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - Simply Wall St

Wed, 01 May 2024
SCYNEXIS (SCYX) Skyrockets 134% Year to Date: Here's Why - Yahoo New Zealand News

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 38 (M)
Shares Float 37 (M)
Held by Insiders 0.8 (%)
Held by Institutions 48.5 (%)
Shares Short 977 (K)
Shares Short P.Month 976 (K)
Stock Financials
EPS 1.38
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.96
Profit Margin 72.1 %
Operating Margin -692.5 %
Return on Assets (ttm) 48.9 %
Return on Equity (ttm) 458.5 %
Qtrly Rev. Growth 21.5 %
Gross Profit (p.s.) 0
Sales Per Share 3.71
EBITDA (p.s.) 1.96
Qtrly Earnings Growth 0 %
Operating Cash Flow 75 (M)
Levered Free Cash Flow 37 (M)
Stock Valuations
PE Ratio 1.69
PEG Ratio 0
Price to Book value 1.19
Price to Sales 0.63
Price to Cash Flow 1.18
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android